サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1632667

分岐部病変の世界市場：市場規模・シェア・動向分析 (用途別・地域別)、セグメント別予測 (2025年～2030年)

Bifurcation Lesions Market Size, Share & Trends Analysis Report, By Application (Coronary, Peripheral), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
分岐部病変の世界市場：市場規模・シェア・動向分析 (用途別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2024年12月26日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

分岐部病変市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の分岐部病変の市場規模は2025年から2030年にかけてCAGR 6.0％を記録し、2030年までに35億米ドルに達する見込みです。

技術開発と償還のための支援的な政府のイニシアチブは、予測期間中に市場を牽引する可能性が高いです。

高齢者人口の増加と不健康なライフスタイルは、心血管障害の発生率増加の原因となっています。さらに、革新的なデバイスの承認・商品化の増加や、今後数年間で分岐部病変の治療のための新しいデバイスの参入が見込まれることも、市場を牽引する可能性が高いです。

加えて、手頃な価格の上昇、低侵襲手術の需要の増加、医療ツーリズムの増加などの要因も、世界全体で分岐部病変手術の需要を押し上げています。様々な調査によると、冠動脈分岐部病変に対する処置は経皮的冠動脈インターベンション全体の約20%を占めています。

分岐部病変市場：分析概要

  • 分岐部病変用デバイスの商品化の増加や、業界各社による研究開発への投資が市場を押し上げる要因となっており、その結果、2025年から2030年までのCAGRは約6.0%と予想されます。
  • 冠動脈血管セグメントは、心臓の複雑な血管網の存在、デバイスの入手可能性の増加、分岐部病変に対する外科的介入に関する意識の高まりにより、2024年に市場の最大シェアを占めました。
  • 末梢血管セグメントは、末梢アプリケーション用デバイス開発のための業界プレイヤーの投資増加や、プラークの正確な検出を容易にする診断の進歩により、今後数年間で有利な成長を示す可能性が高いです。
  • 地域別では、北米が2024年の分岐部病変市場で最大のシェアを占めています。薬剤溶出ステント需要の増加、分岐部病変用デバイスの商品化、主要企業の現地進出などにより、今後も優位性を維持すると予測されています。
  • アジア太平洋地域は、医療インフラの改善、メディアkるツーリズム、同地域の市場参入企業による投資の増加により、今後10年間で最も急速な成長が見込まれています。
  • 同市場の主要企業としては、アボット社、ボストン・サイエンティフィック社、カーディナル・ヘルス社、メドトロニック社、ジョンソン・エンド・ジョンソンサービス社、C.R.バード社、スペクトラネティクス社、テルモメディカル社などが挙げられます。は、バルーン拡張可能な単線ステントデリバリーシステムを備えたTryton Side Branch Stentを開発し、分岐部病変の治療のために側枝動脈に留置できるようにしました。このステントは米国、欧州、中東・アフリカで販売されています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 分岐部病変市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 分岐部病変市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 分岐部病変市場：用途別の推定・動向分析

  • 分岐部病変市場：用途別のダッシュボード
  • 分岐部病変市場：用途別の変動分析
  • 分岐部病変市場：市場規模の予測と動向分析、用途別 (2018～2030年)
  • 冠動脈
  • 末梢血管

第5章 分岐部病変市場：地域別の推定・動向分析 (用途別・地域別)

  • 世界の分岐部病変市場：地域別ダッシュボード
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 最新動向と影響分析：主要メーカー別
  • 企業/競合の分類
  • ベンダー情勢
    • 主要な流通業者・チャネルパートナーの一覧
    • 主要顧客
    • 主要企業の市場シェア分析 (2023年)
    • Boston Scientific Corp.
    • Abbott
    • Cardinal Health
    • Medtronic
    • CR Bard, Inc.
    • Johnson &Johnson Services, Inc.
    • Spectranetics
    • Terumo Medical Corp.
    • Tryton Medical Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Global bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 4 Global bifurcation lesions market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 9 Mexico bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 12 UK bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 14 France bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 15 Italy bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 16 Spain bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 17 Denmark bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 18 Sweden bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 19 Norway bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 22 Japan bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 23 China bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 24 India bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 25 Australia bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 26 Australia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 27 Thailand bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 28 South Korea bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 29 Latin America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 31 Brazil bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 32 Argentina bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 33 MEA bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 35 South Africa bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 36 Saudi Arabia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 37 UAE bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 38 Kuwait bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 39 Participant's overview
  • Table 40 Financial performance
  • Table 41 Key companies undergoing expansions
  • Table 42 Key companies undergoing acquisitions
  • Table 43 Key companies undergoing collaborations
  • Table 44 Key companies launching new product types
  • Table 45 Key companies undergoing partnerships
  • Table 46 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Bifurcation lesions market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Bifurcation lesions market outlook, 2024 (USD Million)
  • Fig. 10 Market Trends & outlook
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Bifurcation lesions application market share analysis, 2024 - 2030 (USD Million)
  • Fig. 14 Bifurcation lesions application market: Segment dashboard
  • Fig. 15 Coronary market, 2018 - 2030 (USD Million)
  • Fig. 16 Peripheral market, 2018 - 2030 (USD Million)
  • Fig. 17 Regional marketplace: Key takeaways
  • Fig. 18 North America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 20 Canada bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 21 Mexico bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 22 Europe bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 23 UK bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 24 Germany bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 25 France bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 26 Italy bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 27 Spain bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 29 Sweden bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 30 Norway bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 31 Asia Pacific bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 32 Japan bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 33 China bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 34 India bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 35 Australia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 36 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 37 Thailand bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 38 Latin America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 39 Brazil bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 40 Argentina bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 41 MEA bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 42 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 43 Saudi Arabia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 44 UAE bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 45 Kuwait bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 46 Strategy framework
目次
Product Code: GVR-1-68038-534-2

Bifurcation Lesions Market Growth & Trends:

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

Bifurcation Lesions Market Report Highlights:

  • Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030
  • The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.
  • The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.
  • Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.
  • The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.
  • Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application Segment
    • 2.2.2. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Bifurcation Lesions Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of congenital heart disease
      • 3.2.1.2. Increasing number of CVD incidence
      • 3.2.1.3. Increasing awareness among the population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Limited awareness and adoption
  • 3.3. Bifurcation Lesions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Bifurcation Lesions Market: Application Estimates & Trend Analysis

  • 4.1. Bifurcation Lesions Market: Application Dashboard
  • 4.2. Bifurcation Lesions Market: Application Movement Analysis
  • 4.3. Bifurcation Lesions Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Coronary
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Peripheral
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bifurcation Lesions Market: Regional Estimates & Trend Analysis by Application, and Region

  • 5.1. Global Bifurcation Lesions Market: Regional Dashboard
  • 5.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 5.3. North America
    • 5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4. Mexico
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Regulatory framework/ reimbursement structure
      • 5.3.4.3. Competitive scenario
      • 5.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.4.2. UK
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Germany
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.4. France
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.5. Italy
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.6. Spain
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.9. Denmark
      • 5.4.9.1. Key country dynamics
      • 5.4.9.2. Regulatory framework/ reimbursement structure
      • 5.4.9.3. Competitive scenario
      • 5.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3. Japan
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4. India
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.5. Australia
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.7. South Korea
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Brazil
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.3. South Africa
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.4. UAE
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.5. Kuwait
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Boston Scientific Corp.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Abbott
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Cardinal Health
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Medtronic
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. C. R. Bard, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Johnson & Johnson Services, Inc.
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Spectranetics
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Terumo Medical Corp.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Tryton Medical Inc.
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives